There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CVS Health (CVS – Research Report), IGM Biosciences (IGMS – Research Report) and Adverum Biotechnologies (ADVM – Research Report) with bullish sentiments.
CVS Health (CVS)
In a report issued on September 5, David S Macdonald from Truist Financial maintained a Buy rating on CVS Health, with a price target of $98.00. The company’s shares closed last Wednesday at $65.51, close to its 52-week low of $64.62.
According to TipRanks.com, Macdonald is a 5-star analyst with an average return of
CVS Health has an analyst consensus of Strong Buy, with a price target consensus of $93.58, which is a 43.1% upside from current levels. In a report issued on August 23, Bank of America Securities also maintained a Buy rating on the stock with a $93.00 price target.
See today’s best-performing stocks on TipRanks >>
IGM Biosciences (IGMS)
In a report issued on September 5, Asthika Goonewardene from Truist Financial maintained a Buy rating on IGM Biosciences, with a price target of $25.00. The company’s shares closed last Wednesday at $6.66.
According to TipRanks.com, Goonewardene has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on IGM Biosciences is a Moderate Buy with an average price target of $18.88.
Adverum Biotechnologies (ADVM)
In a report issued on September 4, Joon Lee from Truist Financial maintained a Buy rating on Adverum Biotechnologies, with a price target of $6.00. The company’s shares closed last Wednesday at $1.76.
According to TipRanks.com, Lee is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adverum Biotechnologies with a $4.33 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CVS:
- CVS Health management to meet with Mizuho
- CVS Health price target lowered to $82 from $85 at Piper Sandler
- Walmart asks pharmacists to take voluntarily wage cuts, Reuters says
- CVS Health (NYSE:CVS) Stock: 3 Reasons Why It’s as Attractive as Ever
- Jefferies healthcare analysts to hold an analyst/industry conference call
